Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma
Background: To improve the selection of patients for ureteroscopy, avoid excessive testing and reduce costs, we aimed to develop and validate a diagnostic urine assay for upper tract urinary carcinoma (UTUC). Methods: In this cohort study we recruited 402 patients from six Hunan hospitals who underw...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/14/3537 |
_version_ | 1797440346581368832 |
---|---|
author | Wei Ouyang Lufeng Luo Junjie Zhang Ran Xu Qiang Lu Zhenzhou Xu Jianye Liu Pei Li Yaqun Zhang Chuanchi Zhou Wei Tang Zhenting Wang Manman Cao Genming Xu Long Wang |
author_facet | Wei Ouyang Lufeng Luo Junjie Zhang Ran Xu Qiang Lu Zhenzhou Xu Jianye Liu Pei Li Yaqun Zhang Chuanchi Zhou Wei Tang Zhenting Wang Manman Cao Genming Xu Long Wang |
author_sort | Wei Ouyang |
collection | DOAJ |
description | Background: To improve the selection of patients for ureteroscopy, avoid excessive testing and reduce costs, we aimed to develop and validate a diagnostic urine assay for upper tract urinary carcinoma (UTUC). Methods: In this cohort study we recruited 402 patients from six Hunan hospitals who underwent ureteroscopy for hematuria, including 95 patients with UTUC and 307 patients with non-UTUC findings. Midstream morning urine samples were collected before ureteroscopy and surgery. DNA was extracted and qPCR was used to analyze mutations in <i>TERT</i> and <i>FGFR3</i> and the methylation of <i>NRN1</i>. In the training set, the random forest algorithm was used to build an optimal panel. Lastly, the Beijing cohort (<i>n</i> = 76) was used to validate the panel. Results: The panel combining the methylation with mutation markers led to an AUC of 0.958 (95% CI: 0.933–0.975) with a sensitivity of 91.58% and a specificity of 94.79%. The panel presented a favorable diagnostic value for UTUC vs. other malignant tumors (AUC = 0.920) and UTUC vs. benign disease (AUC = 0.975). Furthermore, combining the panel with age revealed satisfactory results, with 93.68% sensitivity, 94.44% specificity, AUC = 0.970 and NPV = 98.6%. In the external validation process, the model showed an AUC of 0.971, a sensitivity of 95.83% and a specificity of 92.31, respectively. Conclusions: A novel diagnostic model for analyzing hematuria patients for the risk of UTUC was developed, which could lead to a reduction in the need for invasive examinations. Combining <i>NRN1</i> methylation and gene mutation (<i>FGFR3</i> and <i>TERT</i>) with age resulted in a validated accurate prediction model. |
first_indexed | 2024-03-09T12:06:50Z |
format | Article |
id | doaj.art-978a7775c1de4ec682a369782345709c |
institution | Directory Open Access Journal |
issn | 2072-6694 |
language | English |
last_indexed | 2024-03-09T12:06:50Z |
publishDate | 2022-07-01 |
publisher | MDPI AG |
record_format | Article |
series | Cancers |
spelling | doaj.art-978a7775c1de4ec682a369782345709c2023-11-30T22:57:14ZengMDPI AGCancers2072-66942022-07-011414353710.3390/cancers14143537Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary CarcinomaWei Ouyang0Lufeng Luo1Junjie Zhang2Ran Xu3Qiang Lu4Zhenzhou Xu5Jianye Liu6Pei Li7Yaqun Zhang8Chuanchi Zhou9Wei Tang10Zhenting Wang11Manman Cao12Genming Xu13Long Wang14Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Urology, The Second Xiangya Hospital, Central South University, Changsha 410028, ChinaDepartment of Urology, Hunan Provincial People’s Hospital, First Affiliated Hospital of Hunan Normal University, Changsha 410002, ChinaDepartment of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medical, Central South University, Changsha 410013, ChinaDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaYearth Biotechnology Co., Ltd., Changsha 410205, ChinaDepartment of Urology, Beijing Hospital, Beijing 100000, ChinaDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaYearth Biotechnology Co., Ltd., Changsha 410205, ChinaAffiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou 570100, ChinaYearth Biotechnology Co., Ltd., Changsha 410205, ChinaYearth Biotechnology Co., Ltd., Changsha 410205, ChinaDepartment of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, ChinaBackground: To improve the selection of patients for ureteroscopy, avoid excessive testing and reduce costs, we aimed to develop and validate a diagnostic urine assay for upper tract urinary carcinoma (UTUC). Methods: In this cohort study we recruited 402 patients from six Hunan hospitals who underwent ureteroscopy for hematuria, including 95 patients with UTUC and 307 patients with non-UTUC findings. Midstream morning urine samples were collected before ureteroscopy and surgery. DNA was extracted and qPCR was used to analyze mutations in <i>TERT</i> and <i>FGFR3</i> and the methylation of <i>NRN1</i>. In the training set, the random forest algorithm was used to build an optimal panel. Lastly, the Beijing cohort (<i>n</i> = 76) was used to validate the panel. Results: The panel combining the methylation with mutation markers led to an AUC of 0.958 (95% CI: 0.933–0.975) with a sensitivity of 91.58% and a specificity of 94.79%. The panel presented a favorable diagnostic value for UTUC vs. other malignant tumors (AUC = 0.920) and UTUC vs. benign disease (AUC = 0.975). Furthermore, combining the panel with age revealed satisfactory results, with 93.68% sensitivity, 94.44% specificity, AUC = 0.970 and NPV = 98.6%. In the external validation process, the model showed an AUC of 0.971, a sensitivity of 95.83% and a specificity of 92.31, respectively. Conclusions: A novel diagnostic model for analyzing hematuria patients for the risk of UTUC was developed, which could lead to a reduction in the need for invasive examinations. Combining <i>NRN1</i> methylation and gene mutation (<i>FGFR3</i> and <i>TERT</i>) with age resulted in a validated accurate prediction model.https://www.mdpi.com/2072-6694/14/14/3537upper tract urinary carcinomaliquid biopsyDNA methylationgene mutation |
spellingShingle | Wei Ouyang Lufeng Luo Junjie Zhang Ran Xu Qiang Lu Zhenzhou Xu Jianye Liu Pei Li Yaqun Zhang Chuanchi Zhou Wei Tang Zhenting Wang Manman Cao Genming Xu Long Wang Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma Cancers upper tract urinary carcinoma liquid biopsy DNA methylation gene mutation |
title | Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma |
title_full | Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma |
title_fullStr | Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma |
title_full_unstemmed | Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma |
title_short | Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma |
title_sort | urine cellular dna point mutation and methylation for identifying upper tract urinary carcinoma |
topic | upper tract urinary carcinoma liquid biopsy DNA methylation gene mutation |
url | https://www.mdpi.com/2072-6694/14/14/3537 |
work_keys_str_mv | AT weiouyang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT lufengluo urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT junjiezhang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT ranxu urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT qianglu urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT zhenzhouxu urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT jianyeliu urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT peili urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT yaqunzhang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT chuanchizhou urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT weitang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT zhentingwang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT manmancao urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT genmingxu urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma AT longwang urinecellulardnapointmutationandmethylationforidentifyinguppertracturinarycarcinoma |